Condition: Mammary Neoplasms


rs113994087 in ALK gene and Mammary Neoplasms PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs121913348 in BRAF gene and Mammary Neoplasms PMID 12068308 2002 Mutations of the BRAF gene in human cancer.

PMID 22538770 2012 Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers.

PMID 25157968 2014 Prospective enterprise-level molecular genotyping of a cohort of cancer patients.

rs1057517590 in BRCA1 gene and Mammary Neoplasms PMID 15145354 2004 Nonsense-mediated mRNA decay: terminating erroneous gene expression.

PMID 27257965 2016 Prevalence and Prognostic Role of BRCA1/2 Variants in Unselected Chinese Breast Cancer Patients.

PMID 20516115 2010 Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.

PMID 26344711 2015 Does familial breast cancer and thymoma suggest a cancer syndrome? A family perspective.

PMID 21725363 2012 Functional differences among BRCA1 missense mutations in the control of centrosome duplication.

PMID 6455195 1981 Chromosome damage in G0 X-irradiated lymphocytes from patients with hereditary retinoblastoma.

PMID 25863477 2015 The prevalence and spectrum of BRCA1 and BRCA2 mutations in Korean population: recent update of the Korean Hereditary Breast Cancer (KOHBRA) study.

PMID 22798144 2012 Characteristics and spectrum of BRCA1 and BRCA2 mutations in 3,922 Korean patients with breast and ovarian cancer.

PMID 14576432 2003 BRCT repeats as phosphopeptide-binding modules involved in protein targeting.

PMID 824983 1976 [Simple and rapid technic of grouping of streptococci].

PMID 25366075 2014 One Case of a BRCA1 Germ Line Mutation Ovarian Carcinoma Patient Based on Abnormal Immunohistochemistry Finding.

PMID 7680524 1993 Mutational analysis of a patient with mucopolysaccharidosis type VII, and identification of pseudogenes.

PMID 6848529 1983 Diagnosis of vertebral fractures.

PMID 15117986 2004 Incidence of BRCA1 and BRCA2 mutations in young Korean breast cancer patients.

PMID 3175448 1988 AIDS legislation.

PMID 6852015 1983 Purification and characterization of a new sodium-transport decarboxylase. Methylmalonyl-CoA decarboxylase from Veillonella alcalescens.

PMID 7257965 1980 [The measuring for depth of papillary excavation by microcomputer (author's transl)].

rs1555284442 in BRCA2 gene and Mammary Neoplasms PMID 15145354 2004 Nonsense-mediated mRNA decay: terminating erroneous gene expression.

PMID 27257965 2016 Prevalence and Prognostic Role of BRCA1/2 Variants in Unselected Chinese Breast Cancer Patients.

rs1057519825 in BTK gene and Mammary Neoplasms PMID 24869598 2014 Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.

rs137853011 in CHEK2 gene and Mammary Neoplasms PMID 16914568 2006 CHEK2-positive breast cancers in young Polish women.

PMID 16551709 2006 Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.

PMID 22419737 2012 Response to DNA damage of CHEK2 missense mutations in familial breast cancer.

PMID 27153395 2016 Evaluation of ACMG-Guideline-Based Variant Classification of Cancer Susceptibility and Non-Cancer-Associated Genes in Families Affected by Breast Cancer.

PMID 15649950 2005 Functional and genomic approaches reveal an ancient CHEK2 allele associated with breast cancer in the Ashkenazi Jewish population.

PMID 18085035 2007 Germline CHEK2 mutations in Jewish Ashkenazi women at high risk for breast cancer.

PMID 18571837 2008 Identification and characterization of novel SNPs in CHEK2 in Ashkenazi Jewish men with prostate cancer.

PMID 15145354 2004 Nonsense-mediated mRNA decay: terminating erroneous gene expression.

PMID 28514723 2017 Genomic profiling of pelvic genital type leiomyosarcoma in a woman with a germline CHEK2:c.1100delC mutation and a concomitant diagnosis of metastatic invasive ductal breast carcinoma.

PMID 17721994 2007 Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts.

PMID 22114986 2011 CHEK2 contribution to hereditary breast cancer in non-BRCA families.

rs1057519787 in ERBB2 gene and Mammary Neoplasms PMID 23220880 2013 Activating HER2 mutations in HER2 gene amplification negative breast cancer.

PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

PMID 16397024 2006 Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas.

PMID 25157968 2014 Prospective enterprise-level molecular genotyping of a cohort of cancer patients.

PMID 22046346 2011 Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.

PMID 18413839 2008 EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.

rs1057519857 in ERBB2;MIR4728 gene and Mammary Neoplasms PMID 25157968 2014 Prospective enterprise-level molecular genotyping of a cohort of cancer patients.

PMID 23220880 2013 Activating HER2 mutations in HER2 gene amplification negative breast cancer.

PMID 16397024 2006 Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas.

rs1057519891 in ERBB3 gene and Mammary Neoplasms PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs1057519714 in ESR1 gene and Mammary Neoplasms PMID 24185512 2013 ESR1 ligand-binding domain mutations in hormone-resistant breast cancer.

PMID 24185510 2013 Activating ESR1 mutations in hormone-resistant metastatic breast cancer.

PMID 24398047 2014 Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer.

rs1057519895 in FBXW7 gene and Mammary Neoplasms PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs1057519045 in FGFR2 gene and Mammary Neoplasms PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs1057520036 in FGFR4 gene and Mammary Neoplasms PMID 19946327 2010 The FGFR4 Y367C mutant is a dominant oncogene in MDA-MB453 breast cancer cells.

rs11554273 in GNAS gene and Mammary Neoplasms PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs1057519727 in HERC2 gene and Mammary Neoplasms PMID 23220880 2013 Activating HER2 mutations in HER2 gene amplification negative breast cancer.

PMID 16397024 2006 Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas.

rs104894230 in HRAS;LRRC56 gene and Mammary Neoplasms PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

PMID 25157968 2014 Prospective enterprise-level molecular genotyping of a cohort of cancer patients.

rs121913499 in IDH1 gene and Mammary Neoplasms PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs104894226 in LRRC56;HRAS gene and Mammary Neoplasms PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

PMID 25157968 2014 Prospective enterprise-level molecular genotyping of a cohort of cancer patients.

rs1057519912 in MED12 gene and Mammary Neoplasms PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs1057519737 in MIR4728;ERBB2 gene and Mammary Neoplasms PMID 23220880 2013 Activating HER2 mutations in HER2 gene amplification negative breast cancer.

PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

PMID 16397024 2006 Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas.

PMID 22046346 2011 Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.

PMID 24516025 2014 Response of an ERBB2-mutated inflammatory breast carcinoma to human epidermal growth factor receptor 2-targeted therapy.

PMID 25157968 2014 Prospective enterprise-level molecular genotyping of a cohort of cancer patients.

rs1057519913 in MTOR gene and Mammary Neoplasms PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs80357783 in NBR2;BRCA1 gene and Mammary Neoplasms PMID 27257965 2016 Prevalence and Prognostic Role of BRCA1/2 Variants in Unselected Chinese Breast Cancer Patients.

rs104886003 in PIK3CA gene and Mammary Neoplasms PMID 23888070 2013 PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system.

PMID 20453058 2010 Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models.

PMID 18725974 2008 Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling.

PMID 23066039 2013 PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials.

PMID 15805248 2005 PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma.

PMID 18676830 2008 An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.

PMID 22162589 2012 Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.

PMID 22162582 2012 Phosphatidylinositide-3-kinase inhibitors: addressing questions of isoform selectivity and pharmacodynamic/predictive biomarkers in early clinical trials.

PMID 15647370 2005 Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic.

PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

PMID 15254419 2004 The PIK3CA gene is mutated with high frequency in human breast cancers.

PMID 25157968 2014 Prospective enterprise-level molecular genotyping of a cohort of cancer patients.

PMID 21558396 2011 The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.

rs1057519943 in POLE gene and Mammary Neoplasms PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs1057519946 in PPP2R1A gene and Mammary Neoplasms PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs1057519724 in PTEN gene and Mammary Neoplasms PMID 10555148 1999 Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association.

PMID 20085938 2010 The PI3K pathway as drug target in human cancer.

PMID 20453058 2010 Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models.

PMID 11504908 2001 Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs1057519951 in RHOA gene and Mammary Neoplasms PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs1057520015 in ROCK1 gene and Mammary Neoplasms PMID 20140017 2010 Activating ROCK1 somatic mutations in human cancer.

rs754688962 in SF3B1 gene and Mammary Neoplasms PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs1057519959 in SF3B2 gene and Mammary Neoplasms PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs377767347 in SMAD4 gene and Mammary Neoplasms PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs1057519747 in TP53 gene and Mammary Neoplasms PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

PMID 16489069 2006 The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.

PMID 9569050 1998 Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer.

rs1057520009 in XPO1 gene and Mammary Neoplasms PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.